Abstract
Antipsychotic-induced gastrointestinal hypomotility and, in particular, its manifestation of constipation are common adverse effects in patients with schizophrenia in clinical practice. Serious complications of antipsychotic-induced constipation include ileus, ischaemic bowel disease, colon perforation, aspiration pneumonia, and bacterial septicaemia, which can be life threatening if left untreated, especially in patients prescribed clozapine. The aim of this paper is to review the latest research on the epidemiology, clinical examination methods, pathophysiology, and treatment options and preventive measures for antipsychotic-induced constipation. While clinicians are normally aware of the overall side effects caused by antipsychotics, constipation is often an under-recognized condition despite its relatively high incidence and its impact on daily living. The incidence of constipation differs among individual antipsychotics, but more than 50% of patients prescribed antipsychotics suffer from constipation. Limited fluid intake, poor dietary habits, and a sedentary lifestyle can also worsen constipation. The mechanisms of antipsychotic-induced constipation may be antagonism of cholinergic, histaminergic, and serotonergic receptors, with both parent drug and metabolite(s) contributing to the effects on gastrointestinal motility. Numerous methods, mainly divided into scale evaluations and objective examinations, are applied to evaluate antipsychotic-induced constipation; however, objective examinations have a greater ability to identify cases of gastrointestinal hypomotility since there is often an under-reporting of symptoms in subjective reporting and scale evaluation due to a higher pain threshold, an inability to express pain sensations, and a lack of symptom awareness in these patients. Antipsychotic drug-induced constipation should be closely monitored in patients receiving these medications, with timely intervention to avoid serious gastrointestinal consequences. There is currently no consensus on the efficacy of laxatives in these patients. Further in-depth studies should explore the underlying mechanisms and devise optimal therapeutic approaches to minimize constipation during antipsychotic treatment.
Similar content being viewed by others
References
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry Off J World Psychiatr Assoc (WPA). 2018;17(3):341–56. https://doi.org/10.1002/wps.20567.
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.04.014.
Chen HK, Hsieh CJ. Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: a retrospective cohort study. Schizophr Res. 2018;195:237–44. https://doi.org/10.1016/j.schres.2017.10.024.
Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38(3):592–8. https://doi.org/10.1093/schbul/sbq137.
Thomas N, Jain N, Connally F, Yeung JM, Pantelis C. Prucalopride in clozapine-induced constipation. Aust N Z J Psychiatry. 2018;52(8):804. https://doi.org/10.1177/0004867418774413.
Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759–68. https://doi.org/10.4088/jcp.v69n0509.
Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307–12. https://doi.org/10.4088/JCP.11r06977.
Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99(11):2477–82. https://doi.org/10.1007/s00277-020-04215-y.
De Hert M, De Beugher A, Sweers K, Wampers M, Correll CU, Cohen D. Knowledge of psychiatric nurses about the potentially lethal side-effects of clozapine. Arch Psychiatr Nurs. 2016;30(1):79–83. https://doi.org/10.1016/j.apnu.2015.09.003.
Lu Y-S, Chen Y-C, Kuo S-H, Tsai C-H. Prevalence of antipsychotic drugs related to constipation in patients with schizophrenia. Taiwanese J Psychiatry. 2016;30(4):294–9
Ingimarsson O, MacCabe JH, Sigurdsson E. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. Nord J Psychiatry. 2018;72(7):497–500. https://doi.org/10.1080/08039488.2018.1517189.
De Hert M, Dockx L, Bernagie C, Peuskens B, Sweers K, Leucht S, et al. Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterol. 2011;11:17. https://doi.org/10.1186/1471-230X-11-17.
Koizumi T, Uchida H, Suzuki T, Sakurai H, Tsunoda K, Nishimoto M, et al. Oversight of constipation in inpatients with schizophrenia: a cross-sectional study. Gen Hosp Psychiatry. 2013;35(6):649–52. https://doi.org/10.1016/j.genhosppsych.2013.06.007.
Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29(2):141–6. https://doi.org/10.1097/JCP.0b013e31819a91f1.
Ozbilen M, Adams C, Marley J. Anticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium-and long-term: systematic review and meta-analysis. Curr Med Chem. 2012;19(30):5214–8.
De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, et al. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry J Assoc Eur Psychiatr. 2011;26(1):34–44. https://doi.org/10.1016/j.eurpsy.2010.03.003.
Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114–26. https://doi.org/10.1007/s12325-013-0006-7.
Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD009268.pub2.
Gomez-Revuelta M, Pelayo-Teran JM, Juncal-Ruiz M, Vazquez-Bourgon J, Suarez-Pinilla P, Romero-Jimenez R, et al. Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol. 2020;23(4):217–29. https://doi.org/10.1093/ijnp/pyaa004.
Li H, Shen Y, Wang G, Shi J, Ma C, Xie S, et al. A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiorityrandomized phase iiitrial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophrenia and acute episodes. Psychiatry Res. 2018;259:117–24. https://doi.org/10.1016/j.psychres.2017.07.006.
Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2016;7:832. https://doi.org/10.1002/14651858.CD010832.pub2.
Gomez-Revuelta M, Pelayo-Teran JM, Juncal-Ruiz M, Ortiz-Garciaoz V, Vazquez-Bourgon J, Gonzalez-Pinto A, et al. Long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol. 2018;21(12):1090–101. https://doi.org/10.1093/ijnp/pyy082.
Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, et al. Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology. 2014;231(2):357–66. https://doi.org/10.1007/s00213-013-3241-3.
Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11–24. https://doi.org/10.1097/YIC.0b013e32833e34d9.
Chougule A, Praharaj SK, Bhat SM, Sharma P. Prevalence and factors associated with clozapine-related constipation: an observational study. J Clin Psychopharmacol. 2018;38(1):42–6. https://doi.org/10.1097/jcp.0000000000000824.
Baptista T, Carrizo E, Fernandez E, Connell L, Servigna M, Parra A, et al. Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics. Schizophr Res. 2015;166(1):207–11. https://doi.org/10.1016/j.schres.2015.05.025.
Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125–34.
Iqbal E, Govind R, Romero A, Dzahini O, Broadbent M, Stewart R, et al. The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE. 2020;15(12):e0243437. https://doi.org/10.1371/journal.pone.0243437.
Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M, et al. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. Hum Psychopharmacol Clin Exp. 2021;36(1):1–12.
Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012;81(2):87–97. https://doi.org/10.1159/000332050.
Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:77–85. https://doi.org/10.2147/NDT.S16664.
Hu S, Yao M, Peterson BS, Xu D, Hu J, Tang J, et al. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients. Psychopharmacology. 2013;230(1):3–13. https://doi.org/10.1007/s00213-013-3073-1.
Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone. J Affect Disord. 2016;193:381–90. https://doi.org/10.1016/j.jad.2015.12.060.
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978–87. https://doi.org/10.1001/jama.2014.4310.
Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12. https://doi.org/10.1186/1744-859x-10-12.
Raedler TJ, Reimer J, Wiedemann K. Dose-dependent constipation with higher doses of quetiapine: a case series. Int Clin Psychopharmacol. 2007;22(4):244–6. https://doi.org/10.1097/YIC.0b013e32805b71a3.
Jessurun JG, van Harten PN, Egberts TC, Pijl YJ, Wilting I, Tenback DE. The relation between psychiatric diagnoses and constipation in hospitalized patients: a cross-sectional study. Psychiatry J. 2016;2016:2459693. https://doi.org/10.1155/2016/2459693.
Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17060863.
Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal “slow gut” reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699–709. https://doi.org/10.1007/s40263-017-0448-6.
Every-Palmer S, Inns SJ, Ellis PM. Constipation screening in people taking clozapine: a diagnostic accuracy study. Schizophr Res. 2020;220:179–86. https://doi.org/10.1016/j.schres.2020.03.032.
Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry J Assoc Eur Psychiatr. 2014;29(1):1–10. https://doi.org/10.1016/j.eurpsy.2013.08.001.
Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90(1–3):162–73. https://doi.org/10.1016/j.schres.2006.09.025.
Singh MK, Giles LL, Nasrallah HA. Pain insensitivity in schizophrenia: trait or state marker? J Psychiatr Pract. 2006;12(2):90–102. https://doi.org/10.1097/00131746-200603000-00004.
Jakobsen AS, Speyer H, Norgaard HCB, Karlsen M, Hjorthoj C, Krogh J, et al. Dietary patterns and physical activity in people with schizophrenia and increased waist circumference. Schizophr Res. 2018;199:109–15. https://doi.org/10.1016/j.schres.2018.03.016.
Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2019.12.034.
Bharucha AE, Wald A. Chronic constipation. Mayo Clin Proc. 2019;94(11):2340–57. https://doi.org/10.1016/j.mayocp.2019.01.031.
World Health Organization. Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders. 2012. https://www.who.int/mental_health/mhgap/evidence/psychosis/q6/en/. Accessed 27 May 2021.
Sarangi A, Armin S, Vargas A, Chu VM, Fain K, Nelson J. Management of constipation in patients with schizophrenia—a case study and review of literature. Middle East Curr Psychiatry. 2021;28(1):1–7.
Silverman M, Aroniadis OC, Feuerstadt P, Fenster M, Huisman T, Mansoor MS, et al. Older patients are significantly more likely to have colon ischaemia-associated conditions that are chronic and complex. Aliment Pharmacol Ther. 2019;49(12):1502–8. https://doi.org/10.1111/apt.15268.
Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335–48. https://doi.org/10.2165/00002512-199303040-00004.
Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterology. 2013;144(1):218–38. https://doi.org/10.1053/j.gastro.2012.10.028.
Every-Palmer S, Lentle RG, Reynolds G, Hulls C, Chambers P, Dunn H, et al. Spatiotemporal mapping techniques show clozapine impairs neurogenic and myogenic patterns of activity in the colon of the rabbit in a dose-dependent manner. Front Pharmacol. 2017;8:209. https://doi.org/10.3389/fphar.2017.00209.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–51.
Solismaa A, Kampman O, Lyytikainen LP, Seppala N, Viikki M, Mononen N, et al. Genetic polymorphisms associated with constipation and anticholinergic symptoms in patients receiving clozapine. J Clin Psychopharmacol. 2018;38(3):193–9. https://doi.org/10.1097/JCP.0000000000000885.
Schuster P, Gabriel E, Kufferle B, Strobl G, Karobath M. Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol. 1977;10(4):437–41. https://doi.org/10.3109/15563657709046281.
Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019;33(1):81–91. https://doi.org/10.1007/s40263-018-0587-4.
Hermann B, Wetzel CH, Pestel E, Zieglgansberger W, Holsboer F, Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem Biophys Res Commun. 1996;225(3):957–60. https://doi.org/10.1006/bbrc.1996.1278.
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2003;28(3):519–26. https://doi.org/10.1038/sj.npp.1300027.
Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414. https://doi.org/10.1053/j.gastro.2006.11.002.
Gershon MD. Review article: serotonin receptors and transporters—roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004;20(Suppl 7):3–14. https://doi.org/10.1111/j.1365-2036.2004.02180.x.
Bailey L, Varma S, Ahmad N, Gee S, Taylor DM. Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther Adv Psychopharmacol. 2015;5(5):256–62. https://doi.org/10.1177/2045125315591917.
DiCello JJ, Saito A, Rajasekhar P, Sebastian BW, McQuade RM, Gondin AB, et al. Agonist-dependent development of delta opioid receptor tolerance in the colon. Cell Mol Life Sci CMLS. 2019;76(15):3033–50. https://doi.org/10.1007/s00018-019-03077-6.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377–90. https://doi.org/10.1053/j.gastro.2006.03.008.
Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut–brain interaction. Gastroenterology. 2016;150(6):1257–61. https://doi.org/10.1053/j.gastro.2016.03.035.
McMillan SC, Williams FA. Validity and reliability of the constipation assessment scale. Cancer Nurs. 1989;12(3):183–8. https://doi.org/10.1097/00002820-198906000-00012.
Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–4. https://doi.org/10.3109/00365529709011203.
Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(7):693–703. https://doi.org/10.1111/apt.13746.
Kim ER, Rhee P-L. How to interpret a functional or motility test—colon transit study. J Neurogastroenterol Motil. 2012;18(1):94–9. https://doi.org/10.5056/jnm.2012.18.1.94.
Parthasarathy G, Chen J, Chen X, Chia N, O’Connor HM, Wolf PG, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150(2):367-79.e1. https://doi.org/10.1053/j.gastro.2015.10.005.
Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, et al. The porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs. 2017;31(1):75–85. https://doi.org/10.1007/s40263-016-0391-y.
Grønlund D, Vase L, Knudsen SA, Christensen M, Drewes AM, Olesen AE. Comparison of subjective and objective measures of constipation—employing a new method for categorizing gastrointestinal symptoms. J Pharmacol Toxicol Methods. 2018;94(Pt 2):23–8. https://doi.org/10.1016/j.vascn.2018.08.002.
De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry Off J World Psychiatr Assoc (WPA). 2011;10(1):52.
Dworkin RH. Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr Bull. 1994;20(2):235–48. https://doi.org/10.1093/schbul/20.2.235.
Ohashi K, Himaki D, Nagao K, Kawai M, Gale JD, Furness JB, et al. A selective, high affinity 5-HT 2B receptor antagonist inhibits visceral hypersensitivity in rats. Neurogastroenterol Motil Off J Eur Gastrointestinal Motil Soc. 2010;22(2):69–76. https://doi.org/10.1111/j.1365-2982.2009.01395.x.
De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004;53(10):1520–35. https://doi.org/10.1136/gut.2003.035568.
Lee YJ, Park KS. Understanding the changes in diagnostic criteria for functional constipation in pediatric patients: from rome III to rome IV. J Neurogastroenterol Motil. 2019;25(1):3–5. https://doi.org/10.5056/jnm18199.
Bishara D, Taylor D. Adverse effects of clozapine in older patients: epidemiology, prevention and management. Drugs Aging. 2014;31(1):11–20. https://doi.org/10.1007/s40266-013-0144-2.
Bak M. Monitoring clozapine adverse effects calls for the integration of protocol and good clinical practice. J Clin Psychiatry. 2012;73(10):1313–4. https://doi.org/10.4088/JCP.12com07964.
Hayat U, Dugum M, Garg S. Chronic constipation: update on management. Cleve Clin J Med. 2017;84(5):397–408. https://doi.org/10.3949/ccjm.84a.15141.
Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095. https://doi.org/10.1038/nrdp.2017.95.
Suzuki T, Uchida H, Watanabe K, Kashima H. Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. J Clin Pharm Ther. 2007;32(5):525–7. https://doi.org/10.1111/j.1365-2710.2007.00843.x.
Kwiatkowski M, Denka ZD, White CC. Paralytic ileus requiring hospitalization secondary to high-dose antipsychotic polypharmacy and benztropine. Gen Hosp Psychiatry. 2011;33(2):200.e5-7. https://doi.org/10.1016/j.genhosppsych.2010.10.005.
Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Aust Psychiatry Bull R Aust N Zeal Coll Psychiatr. 2008;16(3):216–9. https://doi.org/10.1080/10398560701882203.
Meyer JM, Cummings MA. Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014;130(1):71–2. https://doi.org/10.1111/acps.12259.
Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013;33(5):713–4. https://doi.org/10.1097/JCP.0b013e3182a1160d.
Damodaran I, Hui KO, Nordin ASA, Yee A, Gill JS, Francis B, et al. An open-label, head to head comparison study between prucalopride and lactulose for clozapine induced constipation in patients with treatment resistant schizophrenia. Healthc (Basel Switz). 2020. https://doi.org/10.3390/healthcare8040533.
Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357–64. https://doi.org/10.2147/cia.s2938.
Nakamura M, Nagamine T. Prevalence and predictors of laxatives use in clozapine-related constipation: an observational study. Int Clin Psychopharmacol. 2021;36(3):162–7. https://doi.org/10.1097/yic.0000000000000354.
Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for antipsychotic-related constipation. Schizophr Bull. 2017. https://doi.org/10.1093/schbul/sbx011.
Rao SS, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol. 2016;13(5):295–305. https://doi.org/10.1038/nrgastro.2016.53.
George J, Hotham R, Melton W, Chapple K. Clozapine-induced stercoral colitis: a surgical perspective. BMJ Case Rep. 2019. https://doi.org/10.1136/bcr-2018-227718.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported by the National Key Research and Development Program of China (2018YFC1314300), the National Natural Science Foundation of China (81971255), the Social Development Foundation of Jiangsu Province, China (No. BE2019610), and the Jiangsu Provincial Medical Talent project of China (ZDRCA2016075).
Conflict of interest
The authors declared no conflicts of interest that are relevant to the contents of this review.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Author contributions
YX drafted and revised the manuscript. NA polished the language and revised the manuscript. YX and NA contributed equally to the work. XRZ designed the framework of manuscript and guided the writing and revision of the manuscript. YX, NA, and XRZ approved the final version and agreed to be accountable for its contents.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Rights and permissions
About this article
Cite this article
Xu, Y., Amdanee, N. & Zhang, X. Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment. CNS Drugs 35, 1265–1274 (2021). https://doi.org/10.1007/s40263-021-00859-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-021-00859-0